688065 Cathay Biotech Inc.
- 37.77
- -0.63-1.64%
Cathay Biotech Inc. News
Cathay Biotech Inc. (688065.SH): repurchased 0.0379% of the company's shares.
On January 2, Glonghui reported that Cathay Biotech Inc. (688065.SH) announced that as of December 31, 2024, the company repurchased 220,946 shares of its stock through the centralized bidding trading system of the Shanghai Stock Exchange, accounting for 0.0379% of the company's total share capital of 583,378,039 shares. The highest price of the buyback was 45.95 yuan/share, the lowest price was 44.08 yuan/share, and the total funds paid amounted to 9,995,695.95 yuan (excluding stamp duty, transaction commissions, and other transaction costs).
Cathay Biotech Inc. (688065.SH): plans to jointly invest with entities like Creative Technology to establish a partnership.
On December 16, Longtenghui reported that Cathay Biotech Inc. (688065.SH) announced that in May 2024, it will sign a tripartite strategic cooperation agreement with the Hefei Municipal Government and China Merchants Innovation Technology Group Co., Ltd. (referred to as "China Merchants Innovation Technology"). The parties will fully leverage their respective advantages in industrial policy guidance, application scenario creation, and biomanufacturing technology innovation to build a synthetic biological materials industry cluster. According to the cooperation arrangement in the strategic agreement, to better promote the industrialization of a series of bio-based polyamide composite materials, the three parties will collaborate to establish related entities to engage in the research and development, production of bio-based polyamide composite materials and.
Cathay Biotech Inc. (688065.SH): The company's controlling Shareholder will change from CIB to Shanghai Yao Xiu.
On December 16, Gelonghui reported that Cathay Biotech Inc. (688065.SH) announced that, according to the "Stock Contribution Agreement" signed by its controlling shareholder Cathay Industrial Biotech Ltd. (referred to as "CIB") on June 25, 2023, as part of the overall plan for the issuance of A-shares to specific targets in 2023, CIB intends to transfer its directly held 116,655,640 shares of RMB ordinary A-shares to the Shanghai Yaoqin Biotechnology Partnership (Limited Partnership) (to be established) (subject to final business approval and registration).
Cathay Biotech Inc. (688065.SH): The private placement application has obtained the approval and registration reply from the China Securities Regulatory Commission.
On December 3, Gelonghui reports that Cathay Biotech Inc. (688065.SH) announced that the company recently received the document from the China Securities Regulatory Commission entitled "Approval of the Issuance of Stocks by Shanghai Cathay Biotech Inc. to Specific Investors" (Zheng Jian Xu Ke [2024] No. 1662), with the content of the approval document as follows: 1. The application for the registration of the issuance of stocks to specific investors is approved. 2. This issuance must be strictly implemented according to the submitted declaration documents and issuance plan to the Shanghai Stock Exchange. 3. This approval is valid for 12 months from the date of registration approval.
Cathay Biotech Inc. (688065.SH): The developed bio-based polyimide continuous fiber composite materials have begun sample trial production and verification in the fields of new energy, modern architecture, transportation logistics, etc.
On November 21, Gelonghui reported that cathay biotech inc. (688065.SH) stated on the investor interaction platform that currently, the bio-based polyamide continuous fiber composite materials developed by the company have begun sample production and validation in the fields of new energy fund, modern construction, and logistics. Based on the cost-performance advantages and market potential of these bio-based new materials, the company has conducted business connections with multiple subsidiaries and joint ventures of China Merchants Group, and several pilot projects are underway.
Cathay Biotech: third quarter report 2024
Third Quarter Report 2024
Cathay biotech inc. (688065.SH) announced its performance for the first three quarters, with a net income of 0.345 billion yuan, a year-on-year increase of 9.97%.
Cathay Biotech Inc. (688065.SH) disclosed its third quarter report for 2024, achieving operating income for the first three quarters...
Is Cathay Biotech (SHSE:688065) Using Too Much Debt?
Cathay Biotech Inc. (688065.SH): The controlling shareholder proposed the company to repurchase shares.
On October 16, Cathay Biotech Inc. (688065.SH) announced that the company's controlling shareholder, Cathay Industrial Biotech Ltd. (referred to as the 'controlling shareholder' or 'CIB'), issued a 'Letter on the Proposal for Cathay Biotech Inc. Shanghai to Repurchase Company Shares.' The controlling shareholder proposed that the company use its own funds to repurchase some of the RMB common shares (A shares) issued by Cathay Biotech Inc. Shanghai through the Shanghai Stock Exchange's trading system using centralized competitive bidding trading. The total amount of the repurchase funds shall not be less than RMB 10 million and not exceed RMB 20 million.
Cathay Biotech Inc. (688065.SH): The company develops bio-based polyamide composite materials, bio-based long-chain polyamide, and other products that can be applied to power batteries, energy storage, automobile thermal management components, etc.
Geelonghui September 18th | Cathay Biotech Inc. (688065.SH) stated on the investor interaction platform that new energy is one of the important application areas of the company's bio-based new materials. The company's developed bio-based polyamide composite materials, bio-based long-chain polyamide, and other products can be applied to power batteries, energy storage, autos' thermal management components, etc. At present, the company and its partners are jointly conducting product trial production and verification.
Cathay Biotech Inc. (688065.SH): Some ultra-long chain dicarboxylic acid varieties can be used for side chain modification of peptide drugs.
Gelonghui, September 18th, Cathay Biotech Inc. (688065.SH) stated on the investor interaction platform that some of the company's ultra-long-chain diacid varieties can be used for side chain modification of peptide drugs, providing long-acting sustained release effects. The company is also actively paying attention to related business opportunities, hoping to create more commercial value with its many years of technical accumulation in synthetic biology.
Cathay Biotech Inc. (688065.SH): Using synthetic biology technology to address the technical bottlenecks in the production process of pentamethylene diisocyanate from multiple angles.
Cathay Biotech Inc. (688065.SH) stated on the interactive platform on September 18 that after nearly ten years of research and development, the company has used synthetic biology technology to address technical bottlenecks in the production process of pentamethylene diisocyanate from multiple perspectives and has registered new substances with the Ministry of Ecology and Environment. Based on the pilot-scale pentamethylene diisocyanate production at its production base in Shandong, the company's 0.05 million ton per year bio-based pentamethylene diisocyanate production line at its Wusu base was put into operation in 2021, marking the first industrialization of pentamethylene diisocyanate products.
Cathay Biotech's (SHSE:688065) Anemic Earnings Might Be Worse Than You Think
Cathay Biotech's H1 Profit Rises 2%, Revenue Jumps 40%; Shares Down 3%
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
Cathay Biotech Inc. (688065.SH) has completed the repurchase of 0.9778 million shares, cost 50.4258 million yuan.
Cathay Biotech Inc. (688065.SH) announced that as of the date of this announcement, the company has completed the repurchase and has actually bought back...
Cathay Biotech Inc. (688065.SH): net income in the first half of the year was 0.247 billion yuan, an increase of 2.31% year-on-year.
On August 15th, Gelon Hui reported that Cathay Biotech Inc. (688065.SH) released its 2024 interim report, achieving revenue of 1.444 billion yuan, a year-on-year increase of 40.16%; net income attributable to shareholders of the listed company was 0.247 billion yuan, a year-on-year increase of 2.31%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.24 billion yuan, a year-on-year increase of 11.34%; basic earnings per share were 0.42 yuan. During the reporting period, the company's revenue increased by 40.16% year-on-year, which was mainly due to the company seizing market opportunities, increasing product sales, and launching new products.
Cathay Biotech Inc. (688065.SH): Cumulative repurchase of 0.17% of shares, the company has completed this repurchase.
On August 15th, Gelonhui reported that Cathay Biotech Inc. (688065.SH) has completed the repurchase, with a total of 977,764 shares repurchased, accounting for 0.17% of the company's total share capital of 583,378,039 shares. The highest repurchase price was 57.37 yuan/share, the lowest price was 36.40 yuan/share, and the average repurchase price was 51.57 yuan/share. The total amount paid was RMB50,425,754.38 (excluding stamp duty, transaction commission and other transaction costs) as of the disclosure date of this announcement.
No Data
